NASDAQ NMS - GLOBAL MARKET · ACON
-1.36% · -$0.0400 · Vol 43.3K
Market closed · last close 4:00 PM ET · price as of 16:00:00 ET
Aclarion Inc

Aclarion Inc

Health Care
$2.91

Veridion Score

Refresh
Score snapshot refresh in progress
Veridion Score History · 90D

Composite trend over time

HISTORY REFRESH IN PROGRESS
REFRESHES DAILY
AI Analysis
Sovereign

Why is ACON moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Catalyst calendar
Dated receipts for ACON are being assembled.
About Aclarion Inc
SERVICES-MEDICAL LABORATORIES
Listed since
2022
Employees
11
Country
US

Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient's low back pain, giving physicians clarity to optimize treatment strategies.

Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$2.94
Day high
$3.04
Day low
$2.84
Previous close
$2.95
52W high
$3.48
-16.38% from high
52W low
$2.74
23% of range
Market cap
$7.3M
EPS
$-16.3400
Shares out
2.5M
Volume
43.3K
VWAP
$2.91
Price history computed in-house
1W
-5.83%
1M
-8.49%
SMA 50 $3.01 · below
SMA 200 $3.01 · below
52W position 23%
Veridion warehouse edge

Warehouse intelligence for ACON.

Disclosure-sourced lobbying and contract detail remains attributed in the full panels below.
Data ledger
Quote and day range
Refresh interval: 30 seconds
Source: Market data
Veridion Score
Coverage building
Chart and risk context
Daily bars with no missing-bar fill
Source: Market data
News and filings
Refresh intervals shown inside each panel
Source: Market news and federal filings
Financials
Statements refresh in progress
SEC Form 4 ledger

ACON insider activity

Aclarion Inc

Score
Coverage building
Pressure
Net buying
Filings
5
Buys / sells
5 / 0
Net value
$51K
Insiders
4
Named filers
BS
Breidbart Scott
Insider
Leadership
NK
Neal David K
Insider
Leadership
NB
Ness Brent
Insider
Leadership
Cluster

4 insiders bought in the last 90 days

Net pressure

Net buying: $51K across loaded Form 4 rows.

Convergence not established

Loaded official disclosures do not show all three sources aligned on this ticker.

Filing dateTrade dateInsiderTitleTypePriceQtyOwnedValueReceipt
2026-05-122026-05-12Breidbart ScottInsiderbuy$3.185,6645,664$18KSEC Form 4
2026-05-122026-05-11Neal David KInsiderbuy$3.102,5002,502$8KSEC Form 4
2026-05-112026-05-11Ness BrentInsiderbuy$3.186,2896,300$20KSEC Form 4
2026-05-082026-05-06Wesemann WilliamInsiderbuy$3.301,5621,563$5KSEC Form 4
2025-12-012025-11-26Ness BrentInsiderbuy$6.201011$62SEC Form 4
Source: SEC EDGAR Form 4. Rows with missing price or quantity are excluded rather than zero-filled.Methodology
Congress · 90D
Congress filing snapshot refresh in progress
Federal contracts

ACON contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for ACON in this window.
Lobbying spend

ACON lobbying filings, year to date.

Registered lobbying filings matched to Aclarion Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for ACON in this window.
Latest news · ACON
Refresh interval: 5 minutes · Source: Market news insights
News snapshot refresh in progress
Analyst ratings
Sovereign unlock shows live analyst consensus for ACON.
Options
Sovereign unlock shows live options positioning for ACON.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.